Intranasal vaccination with protein bodies elicit strong protection against Streptococcus pneumoniae colonization

• DOI: 10.1016/j.vaccine.2021.10.006
• Publication Date: 2021-10-25T13:43:10Z
• Authors: L.F. van Beek; J.D. Langereis; H.B. van den Berg...; J. Gillard; W.S.P. Jong; F.J. van Opzeeland; R. Mesman; L. van Niftrik; I. Joosten; D.A. Diavatopoulos; J. Luirink; M.I. de Jonge
• Keywords: Pneumococcal infections

Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a vaccine formulation. PBs can contain high concentrations antigen, stable and relatively resistant to proteases, release antigen slowly cost-effective manufacture. Yet, the capacity provoke immune responses protection in upper respiratory tract, major entry route pathogens, is largely unknown. In this study, we vaccinated mice intranasally comprising antigens from Streptococcus pneumoniae evaluated level against nasopharyngeal colonization. composed α-helical domain pneumococcal surface protein A (PspAα) provided superior colonization S. compared soluble PspAα. Immunization or induced differences antibody binding pneumococci well highly distinct antigen-specific nasal cytokine profile upon vivo stimulation inactivated pneumoniae. Moreover, immunization conserved putative reduced by mice, both single- multi-antigen conclusion, represent formulation that elicits strong mucosal protection. The versatility platform offers opportunities for development next-generation formulations.